Scynexis, Inc.
SCYNEXIS is a pioneering anti-infective company dedicated to developing innovative drugs to combat infectious diseases, especially fungal infections. Their mission is to positively impact patients' lives worldwide by providing safe, effective, and versatile treatments for life-threatening and community infections. They focus on next-generation antifungals, including the fungerps, to address the growing challenge of drug-resistant fungal pathogens.
Industries
biotechnology
health-care
manufacturing
pharmaceutical
Nr. of Employees
medium (51-250)
Scynexis, Inc.
Durham, North Carolina, United States, North America
Patents
Products
Oral triterpenoid antifungal for vulvovaginal candidiasis
An orally administered triterpenoid-class antifungal tablet developed for treatment of vulvovaginal candidiasis and related community fungal infections.
Oral triterpenoid antifungal for vulvovaginal candidiasis
An orally administered triterpenoid-class antifungal tablet developed for treatment of vulvovaginal candidiasis and related community fungal infections.
Expertise Areas
- Antifungal drug discovery and preclinical development
- Mechanism-of-action studies for antifungals
- Preclinical pharmacokinetics and tissue-distribution
- Formulation development for oral and intravenous delivery
Key Technologies
- Glucan synthase inhibition (mechanistic targeting)
- Triterpenoid small-molecule antifungal chemistry
- In vitro antifungal susceptibility testing
- Pharmacokinetics and tissue distribution studies